Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
NOX 4
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "NOX 4" in MCE Product Catalog:
55
55 Publications Verification
Target:
Forschungsgebiete:
GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC50 of 5 μM.
2
2 Cited Publications
Synonyms: Ewha-18278
Target:
Forschungsgebiete:
APX-115 (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 effectively prevents kidney injury .
2
2 Cited Publications
Synonyms: Ewha-18278 free base; Isuzinaxib free base
Target:
Forschungsgebiete:
APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base effectively prevents kidney injury .
1
Category:
Alkaloids Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Lindera aggregata (Sims) Kosterm.
Target:
1
1
Target:
Forschungsgebiete:
NADPH oxidase-IN-1 is an orally active NADPH oxidase (Nox) inhibitor, related with neuronal inflammation. NADPH oxidase-IN-1 can cross the blood-brain barrier (BBB), inhibits Nox2 and Nox4 with IC50s of 1.9 μM and 2.47 μM, respectively. NADPH oxidase-IN-1 suppresses pro-inflammatory cytokines production and LPS-mediated microglial migration, also has in vivo efficacy .
Art. -Nr.: HY-RS09461
Forschungsgebiete:
NOX4 Human Pre-designed siRNA Set A contains three designed siRNAs for NOX4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS09462
Forschungsgebiete:
Nox4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nox4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-RS09463
Forschungsgebiete:
Nox4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nox4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Art. -Nr.: HY-170540
Forschungsgebiete:
NOX4-IN-1 (Compound 14m) is the inhibitor for NADPH oxidase 4 (NOX4), and blocks the generation of ROS. NOX4-IN-1 inhibits TGF-β1/Smad signaling pathway, decreases the expression of fibrosis-related proteins. NOX4-IN-1 inhibits the cell migration of NRK-49F .
Art. -Nr.: HY-N9097
CAS. Nr.: 122001-32-5
Art. -Nr.: HY-148936
CAS. Nr.: 1990478-58-4
Forschungsgebiete:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GLX481372 is a NADPH Oxidase (NOX) inhibitor. GLX481372 potently inhibits NOX4/5 activities with IC50 values of 0.68 and 0.57 μM. GLX481372 also has weak inhibitory activity against NOX1, NOX2, and NOX3, with IC50 values of 7, 16 and 3.2 μM respectively. GLX481372 can inhibit ROS production. GLX481372 can be used for the researches of inflammation, cardiovascular and metabolic disease, such as diabetes .
Art. -Nr.: HY-N16527
CAS. Nr.: 233690-85-2
Art. -Nr.: HY-153978
Target:
Forschungsgebiete:
GLX481369 is a redox active substance. GLX481369 is a Nox4 inhibitor. GLX481369 has antioxidant effects .
Art. -Nr.: HY-N20728
CAS. Nr.: 2221029-53-2
Target:
Art. -Nr.: HY-100111R
CAS. Nr.: 835598-94-2
Target:
Forschungsgebiete:
GLX351322 (Standard) is the analytical standard of GLX351322 (HY-100111). This product is intended for research and analytical applications. GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC50 of 5 μM.
Art. -Nr.: HY-124487
CAS. Nr.: 1062624-71-8
Forschungsgebiete:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GK-136901 is an orally active, dual Nox1/Nox4 NADPH oxidase inhibitor with a Ki of 160 nM for Nox1 and 165 nM for Nox4. GK-136901 potently blocks high glucose-induced intracellular reactive oxygen species production, p38-MAPK phosphorylation, and upregulation of TGF-β1/2 and fibronectin (fibronectin) in renal cells. GK-136901 also inhibits the proliferation of mouse pulmonary vascular cells under hypoxic conditions. GK-136901 is applicable to the research on the pathogenesis of type 2 diabetic nephropathy, high glucose-related renal lesions and pulmonary hypertension .
Art. -Nr.: HY-P790059
Reinheit: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: NOX4; Kidney Superoxide-Producing NADPH Oxidase; NADPH Oxidase 4; Renal NAD(P)H-Oxidase; KOX-1; Kidney Oxidase-1; KOX; RENOX
Species:
Source:
Art. -Nr.: HY-105111
CAS. Nr.: 93426-60-9
Forschungsgebiete:
P-536 is a ACE inhibitor that also inhibits herpes simplex virus HSV-1 thymidine kinase and Trypanosoma cruzi RNA polymerase. By inhibiting the renin-angiotensin system, downregulating the expression of AT1R and NOX4, and reducing oxidative stress (decreasing plasma hydrogen peroxide (H2O2) and 8-isoprostaglandin levels), P-536 effectively reduces systolic blood pressure and improves vascular reactivity. P-536 also inhibits the replication of DNA/RNA viruses such as HSV-1 by blocking nucleotide metabolism and nucleic acid synthesis, competitively inhibits RNA synthesis in Trypanosoma cruzi, and inhibits amastigote replication, thereby impeding its growth. P-536 is suitable for research on hypertension, insulin resistance, and Chagas disease .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
